The Net Margin of Ascendis Pharma A/S (ASND) is
-31.67%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-31.67%
|
| 2024-12-31 |
-103.97%
|
| 2023-12-31 |
-180.51%
|
| 2022-12-31 |
-1139.63%
|
| 2021-12-31 |
-4931.56%
|
| 2020-12-31 |
-6025.53%
|
| 2019-12-31 |
-1630.03%
|
| 2018-12-31 |
-1229.53%
|
| 2017-12-31 |
-8097.84%
|
| 2016-12-31 |
-1487.30%
|
| Ticker |
Name |
Value |
|
ARNA
|
Arena Pharmaceuticals Inc
|
-1141542.60%
|
|
TGTX
|
TG Therapeutics, Inc.
|
72.56%
|
|
FGEN
|
FibroGen Inc
|
-160.63%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
-1800.58%
|
|
VIE
|
Viela Bio Inc
|
-1293.07%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
22.69%
|
|
LEGN
|
Legend Biotech Corporation
|
-28.85%
|
|
MRTX
|
Mirati Therapeutics Inc
|
-5955.55%
|
|
BAVA.CO
|
Bavarian Nordic A/S
|
22.03%
|
|
BIOPOR.CO
|
Bioporto A/S
|
-203.83%
|
|
BPMC
|
Blueprint Medicines Corp
|
-13.19%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
-40.41%
|
|
SANION.ST
|
Saniona AB
|
65.53%
|
|
ALLR.ST
|
Allarity Therapeutics A/S
|
-16473.80%
|
|
BHVN
|
Biohaven Ltd.
|
-1205.09%
|
|
CRSP
|
CRISPR Therapeutics AG
|
-16569.77%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
-609.85%
|
|
ZEAL.CO
|
Zealand Pharma A/S
|
70.05%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
-3876.27%
|
|
FATE
|
Fate Therapeutics Inc
|
-2051.08%
|
|
IGMS
|
IGM Biosciences LLC
|
-7316.16%
|
|
ORPHA.CO
|
Orphazyme A/S
|
-1731.11%
|
|
RVMD
|
Revolution Medicines, Inc.
|
-3768.28%
|
|
TPTX
|
Turning Point Therapeutics Inc
|
-767.30%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
-1170863.70%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
2.23%
|
|
GMAB.CO
|
Genmab A/S
|
25.89%
|
|
XLRN
|
Acceleron Pharma Inc
|
-179.45%
|
|
CCXI
|
Churchill Capital Corp XI
|
-408.87%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
-148.38%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
-32.45%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
-134.73%
|